Autres langues CSPC Pharmaceutical Group Limited

Actions

1093

HK1093012172

Produits pharmaceutiques

Marché Fermé - Hong Kong S.E. 10:08:03 04/09/2026			Varia. 5j.	Varia. 1 janv.
9,685 ^HKD	+0,78%		+1,63%	+14,89%

01/09	CSPC Pharma : un traitement contre le cancer obtient le statut de 'thérapie innovante' pour une nouvelle indication en Chine	MT
01/09	Le SYS6010 de CSPC Pharma obtient le statut de "thérapie innovante" pour une nouvelle indication en Chine	MT

Autres langues

01/09	CSPC Pharma's Cancer Drug Gets Breakthrough Therapy Designation for New Indication in China
01/09	CSPC Pharma's SYS6010 Gets Breakthrough Therapy Designation for New Indication in China
01/09	CSPC Pharma Initiates Depression Drug Candidate Trial in China
31/08	CSPC Pharma Begins Trial for Weight Management Drug in China
31/08	Cspc Pharmaceutical Group Limited Initiates Phase I Clinical Trial of Syh2092 Injection for Weight Management in Adult Patients with Overweight or Obesity At the First Centre in China
28/08	Cspc Pharmaceutical Group Limited Initiates Phase Ii Clinical Trial of Syh2069 Injection for Weight Management in Adult Patients with Overweight or Obesity At the First Centre in China
27/08	CSPC Pharma Gets Trial Nod for Weight Management Drug in China
27/08	CSPC Pharmaceutical Group Limited Obtains Clinical Trial Approval In China For SYH2092 Injection
26/08	CSPC Pharma's Colorectal Cancer Drug Candidate Gets Fast Track Designation by US FDA
26/08	CSPC Pharma's Lung Cancer Candidate Meets Progression-Free Survival Primary Endpoint
26/08	CSPC Pharmaceutical Group Limited Reports Sys6090 Grants Fast Track Designation by U.S. Fda for Treatment of Patients with Mss/Pmmr Mcrc
26/08	CSPC Pharmaceutical Group Limited Reports SYS6010 Meets Primary Endpoint In Phase III Clinical Study For EGFR-Mutated NSCLC
25/08	CSPC Pharmaceutical Group Limited Obtains Clinical Trial Approval For Recombinant Respiratory Syncytial Virus Vaccine SYS6057 In The U.S
21/08	Bond Yields, Oil Prices Cap Asian Stock Markets
20/08	Pharma sector doubles down on AI amid hopes of slashing costs, timelines
20/08	CSPC Pharmaceutical Group Limited Reports Earnings Results for the Half Year Ended June 30, 2026
20/08	CSPC Pharmaceutical's Attributable Profit More Than Doubles in H1; Shares Jump 14%
20/08	Cspc Pharmaceutical Group Limited Declares Interim Dividend for 2026, Payable on 10 November 2026
19/08	CSPC Pharmaceutical Group Limited Initiates Phase Ib/II Clinical Trial of SYS6090 Injection for Treatment of Hepatocellular Carcinoma at First Centre in China
19/08	Shanghai Shyndec Pharmaceutical Co., Ltd. agreed to acquire 51% stake in China National Medicines Guorui Pharmaceutical Co., Ltd. from CSPC Pharmaceutical Group Limited, Sinopharm Group Co. Ltd. and Sinopharm Group Pharmaceutical Co., Ltd. for approximately CNY 410 million.
18/08	CSPC Pharma Unit's Breast Cancer Drug Application Granted Priority Review in China
18/08	CSPC Pharmaceutical Group Limited Announces New Drug Application for Anbenitamab and Docetaxel for Injection (Albumin-Bound) for First-Line Treatment of Advanced Breast Cancer Accepted by NMPA
18/08	Alphamab Oncology and Shanghai JMT-Bio Technology Co., Ltd. Announces Acceptance Of NDA For Anbenitamab As First-Line Treatment For HER2-Positive Advanced Breast Cancer By The NMPA
12/08	CSPC Pharmaceutical Group Limited Provides Update on the Collaboration, Option and License Agreement with Astrazeneca for the Development of siRNA Drugs
12/08	CSPC Pharma Starts Phase 1 Trial of CAR-T Drug for Relapsed, Refractory Lupus